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Effect of mutations on the sensitivity of human beta-cell 
glucokinase to liver regulatory protein 
M. Veiga-da-Cunha 1, L. Z. Xu  2, Y.-H. Lee 2, D. Marotta 2, S. J. Pilkis 2., E. Van Schaftingen 1 
1 Laboratory of Physiological Chemistry, Institute of Cellular and Molecular Pathology and Universit6 Catholique de Louvain, 
Brussels, Belgium 
2 Department of Biochemistry, Medical School, University of Minnesota, Minneapolis, Minnesota, USA 
Summary Human beta-cell glucokinase and its liver 
counterpart displayed a half-saturating concentration 
of glucose (S0.s) of about 8 mmol/l and a Hill coeffi- 
cient of 1.7, and were as sensitive to inhibition by the 
rat liver regulatory protein as the rat liver enzyme. 
These results indicate that the N-terminal region of 
glucokinase, which differs among these three en- 
zymes, is not implicated in the recognition of the reg- 
ulatory protein. They also suggest that the regulatory 
protein, or a related protein, could modulate the af- 
finity of glucokinase for glucose in beta cells. We 
have also tested the effect of several mutations, 
many of which are implicated in maturity onset dia- 
betes of the young. The mutations affected the affin- 
ity for glucose and for the regulatory protein to differ- 
ent degrees, indicating that the binding site for these 
molecules is different. An AsplSSAla mutation, found 
in the expression plasmid previously thought to en- 
code the wild-type enzyme, increased the affinity for 
glucose by about 2.5-fold without changing the affin- 
ity for the regulatory protein. The mutations that 
were found to decrease the affinity for the regulatory 
protein (Asn166Arg, ValZ°3Ala, AsnZ°4Gln, Lys414Ala) 
clustered in the hinge region of glucokinase and near- 
by in the large and small domains. These results are in 
agreement with the concept that part of the binding 
site for the regulatory protein is situated in the hinge 
region of this enzyme. [Diabetologia (1996) 39: 
1173-1179] 
Keywords Glucokinase, hexokinase, glucokinase reg- 
ulatory protein, MODY, non-insulin-dependent dia- 
betes mellitus. 
Mammalian liver contains a protein inhibitor of glu- 
cokinase, which acts competitively with respect to glu- 
cose [1-2]. The effect of this regulatory protein is en- 
hanced by fructose 6-phosphate and counteracted by 
fructose 1-phosphate, both of which act by binding to 
the inhibitor protein [3]. The regulatory protein inhib- 
its glucokinase by forming a complex with this enzyme; 
kinetic experiments have suggested that glucokinase 
has distinct binding sites for the regulatory protein 
and the substrate analogue N-acetylglucosamine [4]. 
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The regulatory protein is specific for glucokinase; 
it is found in the livers of species that express glu- 
cokinase and is absent in species in which glucoki- 
nase is absent [5]. Its presence in islets is inferred 
from the observations that glucokinase activity in is- 
let homogenates is slightly increased by fructose 1- 
phosphate and that islet homogenates inhibit rat li- 
ver glucokinase in a fructose 1-phosphate-sensitive 
manner [6]. Direct demonstration of the presence 
of the regulatory protein in islet tissue is, however, 
still lacking. Glucokinase partially purified from is- 
let extracts is sensitive to the rat liver regulatory 
protein, but the paucity of the enzyme does not per- 
mit a detailed kinetic analysis of the effect of the 
regulatory protein on islet glucokinase [6]. Beta- 
cell glucokinase differs from its liver counterpart 
[7] by the first 15 amino acids encoded by exon 1 
or 1 '  [8]. 
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The  availabili ty of  r ecombinan t  h u m a n  beta-cel l  
g lucokinase  [9] has made  it possible to s tudy mo re  
careful ly  the  kinetic effects  of rat  liver regu la to ry  
protein.  In this repor t ,  we have also invest igated the 
sensitivity of  various glucokinase mutants ,  some of  
which are found  in matur i ty  onset  diabetes  of  the 
young  ( M O D Y )  [9-13], to the regula tory  p ro te in  to  
ascer ta in  whe the r  these muta t ions  al ter  the affinity 
for  glucose to the same ex ten t  as the affinity for  the 
regula tory  protein.  While this work  was in progress,  
it was found  that  the r ecombinan t  c lone  f rom which 
the express ion vectors  for  h u m a n  islet and h u m a n  li- 
ver  glucokinases were  der ived  con ta ined  a muta t ion  
replacing Asp 158 [14, 15] by an alanine residue.  We 
have  also invest igated the effect  of  this muta t ion .  
Materials and methods 
The regulatory protein was purified from rat liver up to the hy- 
droxylapatite step [16] and was freed of inorganic phosphate 
by gel filtration on Sephadex G-25. Rat liver glucokinase was 
purified from livers as described previously [9]. The prepara- 
tion of recombinant forms of human liver and human beta- 
cell glucokinase (which are actually Asp158Ala mutants), and 
of the site-directed mutants of the latter enzyme was reported 
previously [9-12]. It should be noted that the construction of 
the Asn~66Arg mutant led to the reversion of Ala I5s to an Asp 
residue. The true wild-type enzymes were prepared by "repair- 
ing" the Ala 158 mutation according to the following site-di- 
rected mutagenesis procedure. The 5' (up to nucleotide 480) 
and the 3' (from nucleotide 48I) coding regions of the human 
beta-cell glucokinase cDNA inserted in pBlueScript KS + 
(pBS-HIGKAsp158Ala) were amplified in two separate PCR 
reactions with Pwo DNA polymerase using as primers T7 and 
5' - ATCGATATCTTCGTGCCTCAC - 3', for the 5' region 
and T3 and 5' - AAGGGCATCCTTCTCAACTGG - 3', for 
the 3' region. The glucokinase-specific primers (mismatches 
underlined) were phosphorylated at their Y-ends. The ampli- 
fied fragments (560 and 1355 base pairs [bp]) were restricted 
with Xba I and Barn HI, respectively, and purified by agarose 
gel electrophoresis. They were then simultaneously ligated in 
pBS that had been restricted with both XbaI and BamHI, 
and the resulting construct was used to transform Escherichia 
coli JM 109. The glucokinase insert was checked by sequencing 
to exclude polymerase chain reaction (PCR) errors. The ex- 
pression vector for human wild-type beta-cell glucokinase 
(pET-HIGKAla158Asp) was then constructed by replacing a 
SacII-SacI fragment in the expression vector coding for hu- 
man beta-cell glucokinase Asp~SSAla by the corresponding "re- 
paired" fragment. The expression vector for human wild-type 
liver glucokinase (pET-HLGKAla]SSAsp) was similarly con- 
structed. These "repaired" cDNAs were subsequently used to 
transform E. coli BL21(DE3) pLysS [17] and the recombinant 
proteins were expressed and purified as described [18]. 
Glucokinase was assayed spectrophotometrically at 30 °C in 
a mixture containing, except where otherwise indicated, 
25 mmol/1 Hepes, pH 7.1, 5 mmol/1 glucose, i mmol/l ATE 
1 mmol/1 MgCI2, 1 mmol/1 dithiothreitol, 200 ~tmol/1 fructose 
6-phosphate, 25 mmol/1 KC1, 0.25 mmol/1 phosphoenolpyru- 
vate, 0.15 mmol/1 NADH, 10 ~tg/ml of rabbit muscle lactate de- 
hydrogenase and of pyruvate kinase (desalted by gel filtration). 
For the determination of the affinity of glucokinase for the 
regulatory protein, care was taken to use low concentrations 
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Fig.l. Effect of different concentrations of rat liver regulatory 
protein on the glucose saturation curve of wild type recombi- 
nant human islet glucokinase 
of glucokinase (< 160 pg/1) to avoid overestimation of the true 
affinity constants [16]. For the analysis of glucose saturation 
curves, the Vma x was estimated on Hanes plots from values ob- 
served at high concentrations of substrate (typically 50- 
300 mmol/1) and S05 values on Hill plots. 
Results 
Effect o f  the regulatory protein on the kinetics o f  the 
wild-type enzyme. For  the kinet ic  studies, g lucokinase  
was assayed at p H 7 . 1  and in the p resence  of  
25 mmol/1 KC1. These  condi t ions are opt imal  to s tudy 
the effect  of  the regula tory  pro te in  because  a h igher  
p H  or higher  concen t ra t ion  of  C1- would an tagonize  
its effect  [4]. Figure 1 shows that ,  as for  ra t  l iver glu- 
cokinase,  the glucose sa tura t ion  curve of  the wild- 
type  h u ma n  beta-cel l  g lucokinase  was sigmoidal,  dis- 
playing under  our  assay condit ions a S0. 5 of  approxi-  
mate ly  8 mmol/1 and a Hil l  coeff ic ient  close to  1.7. 
Figure 1 also shows that  rat  liver regu la to ry  pro- 
tein caused an increase in the S0. 5 value  wi thout  
changing Vma x, i.e.,  that  the regula tory  pro te in  be- 
haved  as a compet i t ive  inhibitor.  Plots of 1/v as a 
funct ion of  the concen t ra t ion  of  inhibi tor  at d i f ferent  
concent ra t ions  of  glucose were  l inear  and their  ex- 
t rapola t ions  crossed at a value of abou t  - 0 . 8  U of  
regula tory  pro te in /ml  (Fig.2). Based  on these results, 
it was conc luded  that  the compet i t ive  inhibi t ion con- 
stant  of  beta-cel l  g lucokinase  was 0.8 U regula tory  
protein/ml,  i. e. 4 nmol/1 [16]. A similar value was ob- 
ta ined  with rat  l iver glucokinase  (results not  shown).  
As previously  r e p o r t e d  for  rat  l iver glucokinase [1], 
the inhibi t ion exe r t ed  by the regula tory  pro te in  was 
mo d u l a t e d  by f ructose  6-phosphate ,  which increased 
the inhibit ion, and by f ructose  1-phosphate  which an- 
tagonized  the inhibi t ion (data  not  shown).  Thus, in 
the p resence  of  3.2 U of  regu la to ry  p ro te in  per  ml, a 
half -maximal  effect  of  f ructose  6-phosphate  was ob- 
served at a concen t ra t ion  of  abou t  10 ~tmol/1. At  the 
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Fig.2. Dixon plot of the inhibition of wild type human islet 
glucokinase by the rat liver regulatory protein. The activity 
was measured in the presence of 3 (©), 5 (O), 10 (&) or 20 
(A)  retool/1 glucose 
same concentration of regulatory protein and in the 
presence of 50 ~tmol/1 fructose 6-phosphate, 20 ~tmol/1 
fructose 1-phosphate was needed to release half of 
the inhibition. KC1 and, to a lesser extent, potassium 
acetate were found to release the inhibition exerted 
by the regulatory protein on beta-cell glucokinase 
(data not shown) with similar sensitivities to those pre- 
viously observed with rat liver glucokinase [4]. 
Affinity of glucokinase mutants for glucose and N- 
acetyl-glucosamine. It was of interest to determine 
Fig. 3 a, b. Hill plot (a) Hanes plot (b) of the glucose saturation 
curve of wild type human islet glucokinase. The activity of the 
human islet glucokinase was determined at different concen- 
trations of glucose under the assay conditions described in 
Methods. Data are the means of triplicates + SEM. In (b), the 
regressions shown have been calculated for three sets of glu- 
cose concentrations in retool/l: 1)5 to 20, 2)7.5 to 30 and 
3) 20 to 50; the KmS derived from these regressions were 17.9 
and 5 mmol/1, respectively 
the sensitivity of the various mutant  forms of glucoki- 
nase to the inhibition exerted by the regulatory pro- 
tein. Since some of the mutations alter the affinity 
for glucose and the regulatory protein behaves as a 
competitive inhibitor, it was important to determine 
the affinity for the regulatory protein under compara- 
ble conditions, i.e. at similar degrees of glucose satu- 
ration. The half-saturating concentrations of glucose 
were determined graphically on Hill plots, as exem- 
plified in Figure 3 a for the wild-type beta-cell en- 
zyme. It is apparent that this type of plot was linear 
and that it allowed the safe calculation of the half-sat- 
urating concentration of substrate (8 mmol/l) and the 
Hill coefficient (1.7). Since some authors have analy- 
sed glucokinase kinetics by assuming Michaelis-Men- 
ten kinetics [9-13], we also show the results as Hanes 
plots (Fig. 3 b). As expected for a sigmoidal enzyme, 
this type of plot was curvilinear and different KrnS 
(from 5 to 17 mmol/1 in the example) could be calcu- 
lated depending on the set of data points considered. 
Table 1 lists the S0. 5 values that we observed under 
our experimental conditions. They differ from the K m 
values reported previously [9-13], but this is most 
likely due to the fact that the kinetics were previously 
analysed assuming Michaelis-Menten kinetics. Fur- 
thermore,  some of the proteins tested in this work 
and previously [9-12] are actually double-mutants. 
For the Lys414Ala and the Cys414Glu m u t a n t s  we ob- 
served that the inclusion of 25 mmol/1 KC1 in the as- 
say markedly decreased the $0. 5 value (from 16 to 
2.3 mmol/1 and from 22 to 4.2 mmol/1, respectively), 
whereas no such effect was observed with the wild- 
type enzymes. 
The human beta cell and liver enzymes had the 
same affinities for glucose, the S0. 5 values of the non- 
mutated forms being almost identical to that of rat 
liver glucokinase ( -  8 mmol/1), while the S0. 5 of the 
enzymes with the Asp158Ala mutation was about 
2.5 fold lower. An  S0. 5 value of approximately 
3.5 mmol/1 was also observed with this mutant  under 
the assay conditions of Lange et al. [19]. The mutant 
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Table 1. Kinetic properties of rat liver glucokinase and of recombinant wild type and mutant forms of human islet and liver gluco- 
kinases 
Glucokinase So. 5 h [Regulatory protein] causing 50 % I50 NAG [Glucose] 
(mmol/1) inhibition (mmol/1) (mmol/1) 
at 5 mmol/l at indicated 
glucose (U/ml) [Glucose] (U/ml) 
Rat liver 8 1.74 1 2.1 _+ 0.3 (4) 0.20 8 
Human islet wild type 7.6/7.8 1.75/1.7 1/1 (2) 2.4/2.6 (2) 0.20 8 
Human islet AsplSSAla 3.27 + 0.15 (3) 1.73 ± 0.03 (3) 5.4 _+ 0.42 (3) 2.4/2.8 (2) 0.22 3.3 
Human liver wild type 7.8/8 1.6/1.75 1/1.1 (2) 2.4/2.5 (2) 0.20 8 
Human liver Asp158Ala 3.3/3.4 1.75/1.6 5.57 _+ 0.03 (3) 2.4/3.0 (2) 0.22 3.3 
Asn166Arg 2.7 ± 0.06 (3) 1.22/1.22 6.53 ± 0.57 (3) 3.92 ± 0.4 (3) 0.25 3 
VallS2Meta, AsplSSAla 20.1 + 0.7 (3) 1.62/1.8 0.67 _+ 0.04 (3) 1.57 + 0.09 (3) 0.40 20 
Val2°3Ala a, AsplSSAla 38.5/39.5 1.44/1.37 30/30 (2) 31/32 (2) 0.50 40 
AsnZ°4Gln, Aspa58Ala 200 _+ 26 (4) 1.06 ± 0.02 n.d. 24/22 (2) > 20 200 
GluZ79Glna, Asp158Ala 19.3 _+ 0.33 (3) 1.34 ± 0.06 (3) 1.89 ± 0.07 (4) 3.13 + 0.13 (3) 0.60 20 
Lys4~4Ala, AspI58Ala 2.3 ± 0.17 (3) 1.45 ± 0.01 (3) 14/15 (2) 8.0/7.6 (2) 0.18 2.3 
Lys414Glua, AsplSSAla 4.2 1.37 6.3 3.8 0.18 3 
The effect of the regulatory protein was tested at 5 mmol/1 glu- 
cose or at the concentration indicated in the last column. This 
was also the concentration used to estimate the half inhibitory 
concentration of N-acetylglucosamine (I50 NAG). Results are 
individual values 
ues shown for the 
ported by other 
concentrations, a 
or the means _+ SEM for (n) values. The val- 
inhibition by N-acetylglucosamine were sup- 
measurements performed at other glucose 
Mutations found in subjects with MODY 
2oiO , , 
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Fig. 4. Effect of palmitoylCoA on the activity of wild type rat 
liver and human beta-cell glucokinase and of various mutants. 
The enzymes were assayed at concentrations of glucose close 
to their S05 values (Table 1). (©) Rat liver GK; ( • )  wild type 
islet glucokinase; (l I )  Asn~66Arg; (A) AsplSSAla, Val2°3Ala; 
([]) Asp158Ala, Glu279Gln; (A) AsplsaAla, LysalaAla. All the 
other glucokinases present in Table f but not shown in this fig- 
ure behaved like the wild type beta-cell glucokinase except the 
mutant Lys414Glu which had an intermediate behaviour 
Asn2°4Gln, which was the only one in this series to 
display hyperbolic  kinetics, as indicated by a Hill 
coefficient close to 1. Other  mutat ions  (VallSZMet, 
Val2°3Ala, GluZ79Gln) had decreased affinities for glu- 
cose but  wi thout  impor tant  changes in the sigmoid 
character  of their  glucose saturat ion curves. 
The affinity for N-acetylglucosamine was deter- 
mined by measur ing the concentra t ion of the amino- 
sugar required to inhibit  glucokinase by 50 % at a 
concentra t ion of glucose close to the So. 5 value. For 
the Valt82Met, the Val2°3Ala, the Asn2°4Gln and the 
Glu279Gln mutants,  the decrease in the affinity for 
glucose was accompanied by a decrease in the affinity 
for N-acetylglucosamine.  Lit t le change in affinity for 
this inhibitor was however  observed with the other  
mutants ,  including the Asp15SAla proteins. 
Affinity of glucokinase mutants for the regulatory pro- 
tein and for palmitoylCoA. The sensitivity of the wild- 
type and mutan t  glucokinases to inhibit ion by the reg- 
ulatory protein  was de te rmined  both  at a fixed glu- 
cose concentra t ion (5 mmol/1 glucose) and at a glu- 
cose concentra t ion close to the So. 5 value de te rmined  
under  our exper imental  conditions. The latter is 
expected to reflect  the affinity for the regulatory pro- 
tein independent  of changes in the affinity for glu- 
cose. Care was t aken  to use concentrat ions of glucoki- 
nase lower than  the dissociation constant  of the glu- 
cokinase/regulatory protein  complex (3 x 10 -9 mol/1) 
to avoid overes t imat ion of the inhibit ion constants 
[16]. It should be no ted  that  the Asp158Ala muta t ion  
did not  result in a change in the affinity for the regula- 
tory protein. Four  mutat ions  (Asn166Arg, Val2°3Ala, 
Asn2°4Gln, and Lysal4Ala) caused a significant de- 
crease (> 1.5-fold) in the affinity for the regulatory 
protein while the VallSZMet muta t ion  slightly in- 
creased this affinity. These changes did not  always 
parallel those in the affinity for glucose or N-acetyl- 
glucosamine. Indeed  the Valt82Ala mutant ,  which 
had a decreased affinity for both  glucose and N- 
acetylglucosamine,  showed an increased affinity for 
the regulatory protein,  while the Lys414Ala and the 
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Fig.5. Ribbon drawing of the a-carbon 
backbone of the beta-cell human glu- 
cokinase based on the yeast hexokinase 
structure in the open configuration. All 
the amino acid mutations studied are 
indicated. The residues in green corre- 
spond to mutations that do not affect 
the affinity for the regulatory protein. 
The residues in red and yellow corre- 
spond to the mutations that respec- 
tively decreased or increased the affin- 
ity for the regulatory protein. The resi- 
dues in orange, Glu 51 and Glu 52 and the 
loop Val ls4 to Asp 158, were previously 
shown [18] to decrease the affinity of 
glucokinase for the regulatory protein 
when replaced by corresponding resi- 
dues in rat hexokinase I. The glucoki- 
nase model is represented using the 
MOLSCRIPT software [29] and the co- 
ordinates of Charles et al. [30] 
Asn166Arg mutants had an increased affinity for glu- 
cose compared to their respective controls, and a de- 
creased affinity for the regulatory protein. 
We have also tested the sensitivity of glucokinase 
to long chain acylCoAs. All mutants, with two excep- 
tions, displayed a sensitivity to palmitoylCoA that 
was close, or identical, to that expressed by wild- 
type human glucokinases, which in turn was the 
same as that of the rat liver enzyme. As shown in Fig- 
ure 4, the Lys414Ala and the Glu279Gln mutants dis- 
played a-~ 2.5-fold decrease in the sensitivity to this 
effector. 
Discussion 
The mutation Asp15SAla was found in the expression 
plasmids used in the present study as well as in the 
cDNA produced by Nishi and co-workers [14]. It is 
not known at present if this mutation results from a 
PCR error (part of the complete cDNA produced by 
Nishi and co-workers was obtained by amplification 
with Taq polymerase) or from a cloning artifact. The 
fact that Asp 158 is conserved among glucokinases 
[18] and that the Ala 158 variant remained unnoticed 
until now, despite intensive research of mutations in 
the glucokinase gene, argues against a polymorphism. 
The replacement of this residue by an alanine re- 
sults in a significant increase in the affinity for glu- 
cose. This observation is not surprising since Asp ls8 
is situated in the hinge region of glucokinase (Fig. 5) 
close to residues Val 2°3 and Asn 2°4, which, when mu- 
tated to alanine and glutamine, respectively, lead to 
enzymes with a very low affinity for glucose [20] 
(Table 1). Furthermore it was found recently that the 
replacement of residues Va1154 to Asp 158 by the corre- 
sponding residues of rat hexokinase I results in a ten- 
fold decrease in the affinity for glucose [18]. 
The S0. 5 value of the AsplSSAla mutant  was consis- 
tently found in this work to be about 3.5 mmol/1 while 
the " K i n "  values mentioned in the literature for the 
same enzyme (reported to be the wild-type enzyme) 
range between 8 + 2 and 6 + 0.4 mmol/l [9-12]. This 
inconsistency is not due to differences in the assay 
conditions but most likely results from the use of in- 
appropriate methods to calculate K m values for glu- 
cokinase (the term K m is actually meaningless for a 
sigmoidal enzyme). It is well known that, for enzymes 
with sigmoidal saturation curve, double-reciprocal 
plots are curvilinear. The same is true for Hanes plots, 
though the latter type of plot may give the wrong im- 
pression of linearity at elevated concentrations of 
substrate. It can be demonstrated, however, that for 
an enzyme responding to the Hill equation, there is 
no linear portion in a Hanes plot if h ¢ 1. This is the 
reason why different K m values are calculated de- 
pending on the set of data used (Fig. 3 b). In contrast, 
the use of the Hill plot gives S0 5 values which are in- 
dependent  of the chosen data set (Fig. 3 a). The im- 
portance of correctly determining S0 5 values of glu- 
cokinase has been recently discussed by Cardenas 
[211. 
Previous work performed on xenopus glucokinase 
indicated that the regulatory protein binds to the tip 
of the small domain and to the hinge region of this en- 
zyme [18]. Mutations of residues 51 and 52, as well as 
of residues 141-144 resulted in a remarkable de- 
crease in the affinity for the regulatory protein 
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(Fig. 5). The results obtained in the present work con- 
firm and extend these conclusions. Thus, the muta- 
tions that result in a decrease in the affinity for 
the regulatory protein cluster in the hinge region 
(Val2°3Ala, Asn2°4Gln), in close proximity to Glu 51 
and Glu 52, and in the nearby regions of the small 
(Asn166Arg) and the large domain (Lys414Ala; Fig. 5). 
The increase in affinity induced by the Va1182Met mu- 
tation could be due to a change in the positioning of 
the His141-Leu 144 loop, which appears to play an im- 
portant role in the binding of the regulatory protein 
[18]. The fact that the beta-cell enzyme and the liver 
enzyme have the same affinity for the regulatory pro- 
tein indicates that the fifteen N-terminal amino acids, 
which are located in the large domain, are remote 
from the regulatory protein binding site. 
By binding to the hinge region, the regulatory pro- 
tein is likely to interfere with the closure of the cata- 
lytic cleft, which appears to be a prerequisite for the 
phosphoryl transfer reaction occurring between 
ATP and glucose in hexokinases. 
Until now, only two mutants have been found to 
have a decreased affinity for palmitoylCoA. Both 
mutations involve residues (Lys 414 and Glu 279) that 
are in the large domain of the enzyme. These results 
indicate that the binding site for palmitoylCoA is 
most likely on the "internal" face of the large domain 
(Fig.5). The lack of synergism between palmitoyl- 
CoA and the regulatory protein [16] is probably due 
to the fact their binding sites partially overlap in the 
hinge region. 
A growing body of evidence indicates that glucoki- 
nase plays a critical role in the control of insulin secre- 
tion by the beta cell. Insulin secretion correlates with 
glucose metabolism in beta  cells and glucokinase ap- 
pears to be the rate-limiting enzyme of glycolysis in 
these cells (reviewed in [22-24]). In addition, muta- 
tions of the glucokinase gene that result in the synthe- 
sis of inactive enzyme or enzyme with reduced activity 
lead to a form of non-insulin-dependent diabetes 
called MODY, which is characterized by a decreased 
insulin secretion (reviewed in [25-26]). This condition 
is inherited in an autosomal dominant fashion indicat- 
ing that a 50 % decrease or even a decrease of smaller 
magnitude in the activity of glucokinase is sufficient 
to cause a significant reduction in insulin secretion. 
The fact that islet glucokinase is sensitive to the 
regulatory protein indicates that a similar type of 
mechanism to that found in liver could operate in is- 
let cells. Equally, since fructose 1-phosphate was 
found to stimulate the activity of glucokinase in ex- 
tracts of islets [6, 27], this indicates that these cells 
could contain a regulatory protein that is similar or 
related to that found in liver. Interestingly, low 
amounts of regulatory protein m R N A  were found in 
rat islets [27]. However,  it remains to be seen if the 
concentration of regulatory protein is sufficient to ex- 
ert a significant inhibition in vivo. 
Sturis and co-workers [28] have shown that, in sev- 
eral subjects with mutations in the glucokinase gene, 
insulin secretion was reduced compared to that in 
control subjects but less than predicted from the cal- 
culated decrease in glucokinase flux, suggesting that 
there are compensatory changes. One possibility is 
upregulation of the glucokinase expression as a result 
of the increase in the blood glucose level [26]. The 
second possibility is a decrease in the inhibitory effect 
of the regulatory protein. The present work shows 
that this could be  the case for the Val2°3Ala mutant, 
which has a reduced affinity for the regulatory pro- 
tein. Patients harbouring this mutation were found 
to have reduced rates of insulin secretion but this re- 
duction was less than predicted by loss of enzymic ac- 
tivity [26]. 
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